FIGURE 6 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Treatment induced changes in FDG uptake by PET imaging and in the levels of pAKT by IHC in WHIM29 and WHIM34. Representative images of FDG PET scan of tumor-bearing mice performed pretreatment and posttreatment (on day 2, 4 hours following drug dosing) with either vehicle, copanlisib (10 mg/kg i.v., on day 1, and on day 2), eribulin (0.2 or 0.3 mg/kg i.p., on day 1), or the combination of eribulin and copanlisib for WHIM29 (A) and WHIM34 (B). Quantification of average SUV by FDG PET scan of tumor-bearing mice performed pretreatment and posttreatment with either copanlisib, eribulin, or the combination of copanlisib and eribulin in WHIM29 (n = 5; C) and WHIM34 (n = 5; D). ***, P < 0.001; ****, P < 0.0001. Representative IHC images for pAKT473 and cleaved PARP on tumor tissue sections harvested on day 3, following treatment with either vehicle, copanlisib (10 mg/kg i.v., on day 1, and on day 2), eribulin (0.2 or 0.3 mg/kg i.p., on day 1), or the combination of eribulin and copanlisib for WHIM29 (E) and WHIM34 (F).